AN2 Therapeutics, Inc. (ANTX) stock
Close on Nov 12, 2026Market cap $167.55MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $167.55M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 2.22
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$34.84M
- EPS, diluted
- -$0.93
- Book value per share
- $1.64
- Diluted shares
- 46M
Trading
- Next earnings
- Mar 16, 2027 (estimated, after the close)
- Previous close
- $4.46
- Open
- $4.48
- Day's range
- $4.34 – $4.75
- Volume
- 186,344
- Average volume (20 days)
- 254,925
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.91
- 52-week range
- $1.00 – $7.19
- RSI (14 days)
- 53.7
- Volatility (1 year)
- 133.9%
- Relative volume
- 0.73×
- WACC
- 9.5%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ANTX | S&P 500 | Difference | ANTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +3.3% | -2.7% | +6.0 pts | ||
| 3 months | -29.3% | -1.7% | −27.6 pts | ||
| Year to date | +289.5% | +11.9% | +277.6 pts | ||
| 1 year | +276.3% | +12.0% | +264.3 pts | ||
| 3 years | -69.0% | +78.2% | −147.1 pts | -32.3% | +21.2% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Press releases
Releases AN2 Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Results
- Results
- Update
About AN2 Therapeutics
Pharmaceutical Preparations
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics using its proprietary boron chemistry platform. Its research and clinical development pipeline spans hematologic conditions, infectious diseases, and oncology. The company's lead clinical candidate, epetraborole, is being developed for adult patients with phlebotomy-dependent polycythemia vera and individuals suffering from Mycobacterium abscessus complex lung disease. Another clinical asset, AN2-502998, targets patients with chronic Chagas disease. In addition, AN2 conducts global health initiatives aimed at addressing severe bacterial infections, such as melioidosis and tuberculosis, in underserved populations worldwide.
Company profile, executives and historyAN2 Therapeutics stock: common questions
What is AN2 Therapeutics's stock price?
ANTX closed at $4.44 on Nov 12, 2026, down 0.45% on the day. Over the past 52 weeks it traded between $1.00 and $7.19.
What is AN2 Therapeutics's market cap?
AN2 Therapeutics was worth $167.55M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ANTX's P/E ratio?
AN2 Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.93), so it has no meaningful P/E ratio.
Does AN2 Therapeutics pay a dividend?
No. AN2 Therapeutics has not paid a cash dividend over the last twelve months.
When does AN2 Therapeutics report earnings next?
AN2 Therapeutics is expected to report Q4 FY2026 results on Mar 16, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has ANTX stock performed over the past year?
Including dividends, ANTX returned +276.3% over the past year, against +12.0% for the S&P 500.
How many ANTX shares are sold short?
2M shares were sold short at the latest FINRA report, 8.11% of the float, or 9.2 days of average trading volume.
Who are AN2 Therapeutics's competitors?
Companies most similar to AN2 Therapeutics by business, industry and size include PLRX, CNTB, YARW, GRI, ACRS.
See a number that looks wrong?